Cellectis (NASDAQ:CLLS) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Cellectis (NASDAQ:CLLS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. The firm had revenue of $15.50 million for the quarter, compared to analyst estimates of $10.74 million. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%.

Cellectis Trading Down 0.9%

CLLS stock opened at $3.45 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.63. Cellectis has a fifty-two week low of $1.10 and a fifty-two week high of $5.48. The firm’s 50-day simple moving average is $3.86 and its 200 day simple moving average is $3.92.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC acquired a new stake in shares of Cellectis in the fourth quarter valued at approximately $34,000. Acadian Asset Management LLC grew its holdings in Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after buying an additional 26,461 shares in the last quarter. Virtu Financial LLC bought a new position in Cellectis in the 3rd quarter worth approximately $72,000. Millennium Management LLC increased its position in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares during the period. Finally, Citadel Advisors LLC bought a new stake in Cellectis during the 3rd quarter valued at $633,000. Institutional investors own 63.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CLLS. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, January 21st. Jefferies Financial Group started coverage on shares of Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Clear Str raised Cellectis to a “strong-buy” rating in a report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cellectis has an average rating of “Moderate Buy” and an average price target of $6.33.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.